IL218797A - Combination of n - {3 - [3 - cyclopropyl - 5 - (2 - fluoro - 4 - iodo - phenylamino) - 6, 8 - dimethyl - 2, 4, 7, trioxo - 3, 4, 6, 7 - tetrahydro - 2h - pyrido [4, 3 – d] pyrimidine – 1 – yl] phenyl} acetamide dimethyl sulfoxide, and n - {(1s) –2– amino-1 - [(3, 4-diplorophenyl) methyl] ethyl} - 5-Chloro-4 - (4-Chloro-Methyl-1 H - Google Patents

Combination of n - {3 - [3 - cyclopropyl - 5 - (2 - fluoro - 4 - iodo - phenylamino) - 6, 8 - dimethyl - 2, 4, 7, trioxo - 3, 4, 6, 7 - tetrahydro - 2h - pyrido [4, 3 – d] pyrimidine – 1 – yl] phenyl} acetamide dimethyl sulfoxide, and n - {(1s) –2– amino-1 - [(3, 4-diplorophenyl) methyl] ethyl} - 5-Chloro-4 - (4-Chloro-Methyl-1 H

Info

Publication number
IL218797A
IL218797A IL218797A IL21879712A IL218797A IL 218797 A IL218797 A IL 218797A IL 218797 A IL218797 A IL 218797A IL 21879712 A IL21879712 A IL 21879712A IL 218797 A IL218797 A IL 218797A
Authority
IL
Israel
Prior art keywords
chloro
methyl
furancarboxamide
trioxo
pyrido
Prior art date
Application number
IL218797A
Other languages
English (en)
Hebrew (he)
Other versions
IL218797A0 (en
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IL218797A0 publication Critical patent/IL218797A0/en
Publication of IL218797A publication Critical patent/IL218797A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL218797A 2009-09-23 2012-03-22 Combination of n - {3 - [3 - cyclopropyl - 5 - (2 - fluoro - 4 - iodo - phenylamino) - 6, 8 - dimethyl - 2, 4, 7, trioxo - 3, 4, 6, 7 - tetrahydro - 2h - pyrido [4, 3 – d] pyrimidine – 1 – yl] phenyl} acetamide dimethyl sulfoxide, and n - {(1s) –2– amino-1 - [(3, 4-diplorophenyl) methyl] ethyl} - 5-Chloro-4 - (4-Chloro-Methyl-1 H IL218797A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24501909P 2009-09-23 2009-09-23
PCT/US2010/049946 WO2011038082A1 (en) 2009-09-23 2010-09-23 Combination

Publications (2)

Publication Number Publication Date
IL218797A0 IL218797A0 (en) 2012-06-28
IL218797A true IL218797A (en) 2014-11-30

Family

ID=43796197

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218797A IL218797A (en) 2009-09-23 2012-03-22 Combination of n - {3 - [3 - cyclopropyl - 5 - (2 - fluoro - 4 - iodo - phenylamino) - 6, 8 - dimethyl - 2, 4, 7, trioxo - 3, 4, 6, 7 - tetrahydro - 2h - pyrido [4, 3 – d] pyrimidine – 1 – yl] phenyl} acetamide dimethyl sulfoxide, and n - {(1s) –2– amino-1 - [(3, 4-diplorophenyl) methyl] ethyl} - 5-Chloro-4 - (4-Chloro-Methyl-1 H

Country Status (14)

Country Link
US (2) US20120322817A1 (https=)
EP (1) EP2480084B1 (https=)
JP (2) JP2013505939A (https=)
KR (1) KR20120099219A (https=)
CN (1) CN102770026B (https=)
AU (1) AU2010298277B2 (https=)
BR (1) BR112012006693A2 (https=)
CA (1) CA2775124A1 (https=)
EA (1) EA021951B1 (https=)
ES (1) ES2527625T3 (https=)
IL (1) IL218797A (https=)
MX (1) MX2012003546A (https=)
WO (1) WO2011038082A1 (https=)
ZA (1) ZA201202173B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130217710A1 (en) * 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
JP2020530498A (ja) * 2017-08-11 2020-10-22 キュアマッチ インコーポレイテッドCurematch, Inc. 癌における複数の変異を標的とする薬物の組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3401A1 (fr) * 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
AU2005252110B2 (en) * 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
JP3821154B1 (ja) * 2005-03-16 2006-09-13 いすゞ自動車株式会社 排気ガス浄化方法及び排気ガス浄化システム
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt

Also Published As

Publication number Publication date
JP2013505939A (ja) 2013-02-21
EA201270445A1 (ru) 2013-03-29
ZA201202173B (en) 2012-11-28
CN102770026A (zh) 2012-11-07
EP2480084A4 (en) 2013-02-20
MX2012003546A (es) 2012-09-07
WO2011038082A1 (en) 2011-03-31
JP2016106092A (ja) 2016-06-16
IL218797A0 (en) 2012-06-28
EP2480084A1 (en) 2012-08-01
CN102770026B (zh) 2015-04-01
AU2010298277B2 (en) 2014-07-03
ES2527625T3 (es) 2015-01-27
AU2010298277A1 (en) 2012-04-19
CA2775124A1 (en) 2011-03-31
KR20120099219A (ko) 2012-09-07
EP2480084B1 (en) 2014-11-12
BR112012006693A2 (pt) 2015-09-08
US20150094321A1 (en) 2015-04-02
US20120322817A1 (en) 2012-12-20
EA021951B1 (ru) 2015-10-30

Similar Documents

Publication Publication Date Title
CL2013001779A1 (es) Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer.
IL194835A (en) History of cyclohexylpyrazole-lactam, an intermediate substance for their use in the preparation of drugs
SI2069342T1 (sl) Derivati aril fenil imidazo a piridinov njihova priprava in njihova terapevtska uporaba
IL205665A (en) The history of terroiril, the process of preparing them, the drugs containing them and their use in the preparation of drugs
IL248246A0 (en) (5r,2s)-6-(benzyloxy/allyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylates, process for their preparation and use of (5r,2s)-tert-butyl-6 -(benzyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylate for the preparation of anti-infective drugs
IL186881A (en) Pyrido derivatives [3,2– d] pyrimidine and their uses for the manufacture of drugs against hcv
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
EP2006284A4 (en) DICYCLOOCTANE DERIVATIVES, METHOD OF MANUFACTURE AND MEDICAL APPLICATIONS THEREOF
IL180597A0 (en) Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
IL216238A0 (en) 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
IL177283A (en) Pyrazolopyrimidine compounds, their use in the preparation of medicines and pharmaceuticals containing them
IL198289A (en) Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
IL197877A (en) Uses of aminomethyl-4-imidazole derivatives for the preparation of medications and medications containing them
IL218797A (en) Combination of n - {3 - [3 - cyclopropyl - 5 - (2 - fluoro - 4 - iodo - phenylamino) - 6, 8 - dimethyl - 2, 4, 7, trioxo - 3, 4, 6, 7 - tetrahydro - 2h - pyrido [4, 3 – d] pyrimidine – 1 – yl] phenyl} acetamide dimethyl sulfoxide, and n - {(1s) –2– amino-1 - [(3, 4-diplorophenyl) methyl] ethyl} - 5-Chloro-4 - (4-Chloro-Methyl-1 H
IL196785A0 (en) Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
WO2012022919A3 (fr) Formulations à base de nalbuphine et leurs utilisations
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
IL196525A (en) A history of spirocyclic azindole, a process for their preparation and medications containing them
IL188643A (en) Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
IL215285A0 (en) Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
WO2007144169A3 (en) Entacapone-derivatives
IL217293A (en) Annotations of 9,8,7,6-tetrahydropyrimido {{a-2,1 pyramidine-4-one)
TWI366457B (en) Use of a beta2-adrenoceptor agonist for the preparation of a dermatological medicament
SI2448939T1 (sl) Derivati 2,3-dihidro-1H-imidazo(1,2-a)pirimidin-5-ona, njihova priprava in farmacevtska uporaba

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees